Home
by rumbeando Mon Dec 28, 2020 6:09 pmhttps://www.dw.com/en/biontech-pfizer-delays-covid-vaccine-deliveries-to-8-eu-nations/a-56074466BioNTech-Pfizer delays COVID vaccine deliveries to 8 EU nations
The vaccine supply chain appears to have run into trouble just one day after Europe began its mass immunization program.
BioNTech-Pfizer has postponed the delivery of new batches of its coronavirus vaccine to eight European nations including Spain, the Spanish health ministry said on Monday.
The hold-up is due to a "problem in the loading and shipment process" at its plant in Belgium, the health ministry said in a statement, citing the Spanish branch of Pfizer.
The Spanish health ministry did not specify which European nations aside from Spain have been affected.
The delay comes a day after Europe began its COVID-19 immunization program.
Delay 'linked to' temperature
Health Minister Salvador Illa told Spanish radio network SER that the delay was due to a problem "linked to the control of the temperature" of the shipments which was "apparently fixed."
The vaccine, which uses mRNA technology, is extremely sensitive to heat. It is stored at nearly -70 degrees Celsius (-112°F) ahead of shipping, before being sent to distribution centres in specially designed cool boxes filled with dry ice.
On arrival, it must be kept at 2°C to 8°C for it to remain effective for up to five days.
Germany reports similar issue
Several German cities reported similar delays in receiving and administering coronavirus BioNTech-Pfizer on Monday after temperature trackers showed that they may not have been cold enough due to inconsistencies in the cold chain.
Tobias Kurth, epidemiologist and director of the Institute of Public Health at Berlin's Charite hospital in Berlin told DW that Germany was already struggling with the low number of vaccines available. "The issue is that we don't have enough vaccines available in the first weeks or months. So the mass vaccination will likely start in March or even April," he said.
German Health Minister Jens Spahn told public broadcaster ZDF on Monday that the country "was doing everything together with BioNTech-Pfizer" to ramp up domestic production of the coronavirus vaccine in the country.
He said he hoped to get a production facility up and running in Marburg, in the central German state of Hesse, by February or March.
When will the EU's vaccinations arrive?
The distribution of an initial 200 million doses of the COVID-19 vaccine developed BioNTech-Pfizer is scheduled to be completed for the EU by September, a spokesman for the EU Commission told news agency Reuters on Monday.
He added that talks were underway to agree the delivery of a further 100 million additional doses which are optional under the contract sealed with the two companies.
VAKCINA
- Posts : 13817
Join date : 2016-02-01
- Posts : 52540
Join date : 2017-11-16
Citam da je Argentina do sada nabavila 300k Sputnik V vakcine i dogovorila 10m. Kako to da ovi nisu uspeli da dogovore sa nasim "strateskim partnerima" nesto takvo? Pri tom, uopste ne mislim da su nesto krivi Rusi za to konkretno. Sta je sad, i Argentina "izuzetno bogata zemlja"?
- Guest
Vođa je posvećen Vašingtonu, ili bar to Moskva tako vidi.
- Posts : 13817
Join date : 2016-02-01
https://www.livemint.com/science/health/efficacy-of-oxford-jabs-at-95-if-given-3-months-apart-sii-11609181643451.htmlEfficacy of Oxford jabs at 95% if given 3 months apart: SII
- SII is manufacturing 50-60 million doses of Covishield a month and will increase its capacity to 100 million doses by March after commissioning its third plant.
AstraZeneca Plc will soon release data showing that the effectiveness of its covid-19 vaccine rises to as much as 95% if the two shots are separated by about 2-3 months, said Adar Poonawalla, chief executive of Serum Institute of India (SII), the British company’s manufacturing partner.
“You’ll be hearing some good news from the UK very soon. It would be a 90-95% effective vaccine if you just keep a two-to-three months’ gap between dose 1 and dose 2. They will make that public with documentation," Poonawalla said at a press conference on Monday. He was speaking at the launch of the company’s pneumococcal conjugate vaccine, the first such indigenous vaccine, under the brand Pneumosil.
- Posts : 52540
Join date : 2017-11-16
buffalo bill wrote:Vođa je posvećen Vašingtonu, ili bar to Moskva tako vidi.
What Pista said
- Posts : 16552
Join date : 2014-11-06
mislim da je argentina učestvovala i u testiranju sputnik v
- Posts : 13817
Join date : 2016-02-01
Obavezno pročitajte članak o ovoj neverovatnoj ženi koja bi lako mogla dobiti Nobelovu nagradu za ovo otkriće:
https://www.wired.co.uk/article/mrna-coronavirus-vaccine-pfizer-biontechHow mRNA went from a scientific backwater to a pandemic crusher
For decades, Katalin Karikó's work into mRNA therapeutics was overlooked by her colleagues. Now it's at the heart of the two leading coronavirus vaccines
- Spoiler:
By DAVID COX
Wednesday 2 December 2020
In 1995, Katalin Karikó was at her lowest ebb. A biochemist at the University of Pennsylvania (UPenn), Karikó had dedicated much of the previous two decades to finding a way to turn one of the most fundamental building blocks of life, mRNA, into a whole new category of therapeutics.
More often than not, Karikó found herself hitting dead ends. Numerous grant applications were rejected, and an attempt to raise funding from venture capitalists in New York to form a spin-off company had proved to be a fruitless endeavour. ”They initially promised to give us money, but then they never returned my phone calls,” she says.
By the mid 1990s, Karikó’s bosses at UPenn had run out of patience. Frustrated with the lack of funding she was generating for her research, they offered the scientist a bleak choice: leave or be demoted. It was a demeaning prospect for someone who had once been on the path to a full professorship. For Karikó’s dreams of using mRNA to create new vaccines and drugs for many chronic illnesses, it seemed to be the end of the road.
Thirty four years earlier, the discovery of mRNA had been announced amidst a clamour of scientific excitement in the summer of 1961. For more than a decade, researchers in the US and Europe had been attempting to unravel exactly how DNA is involved in the creation of proteins – the long strings of amino acids that are vital to the growth and functioning of all life forms.
It transpired that mRNA was the answer. These molecules act like digital tape recorders, repeatedly copying instructions from DNA in the cell nucleus, and carrying them to protein-making structures called ribosomes. Without this key role, DNA would be nothing but a useless string of chemicals, and so some have dubbed mRNA the ‘software of life.’
At the time the nine scientists credited with discovering mRNA were purely interested in solving a basic biological mystery, but by the 1970s the scientific world had begun to wonder if it could exploit this cellular messaging system to turn our bodies into medicine-making factories.
Artificial mRNA, designed and created in a petri dish and then delivered to the cells of sick patients through tiny packages called nanoparticles, offered a way of instructing the body to heal itself. Research groups around the world began looking into whether mRNA could be used to create the vaccines of the future by delivering messages to cells, teaching them to create specific antibodies to fight off a viral infection. Others started investigating whether mRNA could help the immune system recognise and destroy cancerous tissue.
Karikó was first exposed to these ideas as an undergraduate student in 1976, during a lecture at the University of Szeged in her native Hungary. Intrigued, she began a PhD, studying how mRNA might be used to target viruses. While the concept of gene therapy was also beginning to take off at the same time, capturing the imagination of many scientists, she felt mRNA had the potential to help many more people.
“I always thought that the majority of patients don’t actually need new genes, they need something temporary like a drug, to cure their aches and pains,” she said. “So mRNA was always more interesting to me.”
At the time, the technology required to make such grand ambitions a reality did not yet exist. While scientists knew how to isolate mRNA from cells, creating artificial forms was not possible. But in 1984, the American biochemist Kary Mullis invented polymerase chain reaction (PCR), a method of amplifying very small amounts of DNA so it can be studied in detail. By 1989, other researchers had found a way to utilise PCR to generate mRNA from scratch, by amplifying DNA strands and using an enzyme called RNA polymerase to create mRNA molecules from these strands. “For scientists working on mRNA, this was very empowering,” said Karikó. “Suddenly we felt like we could do anything.”
With an mRNA boom taking place on the other side of the Atlantic, Karikó decided it was time to leave Hungary and head for the US. So in 1985, she accepted a job at Temple University and moved to Philadelphia along with her husband, two year old daughter, and a teddy bear with £900 sewn into it – the proceeds from the sale of their car on the black market.
It did not take long for the American dream to sour. After four years, she was forced to leave Temple University for neighbouring UPenn after a dispute with her boss, who then attempted to have her deported. There she began working on mRNA therapies which could be used to improve blood vessel transplants, by producing proteins to keep the newly transplanted vessels alive.
However, by the early to mid 1990s, some of the early excitement surrounding mRNA was beginning to fade. While scientists had cracked the problem of how to create their own mRNA, a new hurdle had emerged. When they injected it into animals it induced such a severe inflammatory response from the immune system that they died immediately. Any thoughts of human trials were impossible.
This was a serious problem, but one Karikó was determined to solve. She recalls spending one Christmas and New Year’s Eve conducting experiments and writing grant applications. But many other scientists were turning away from the field, and her bosses at UPenn felt mRNA had shown itself to be impractical and she was wasting her time. They issued an ultimatum, if she wanted to continue working with mRNA she would lose her prestigious faculty position, and face a substantial pay cut.
”It was particularly horrible as that same week, I had just been diagnosed with cancer,” said Karikó. “I was facing two operations, and my husband, who had gone back to Hungary to pick up his green card, had got stranded there because of some visa issue, meaning he couldn’t come back for six months. I was really struggling, and then they told me this.”
While undergoing surgery, Karikó assessed her options. She decided to stay, accept the humiliation of being demoted, and continue to doggedly pursue the problem. This led to a chance meeting which would both change the course of her career, and that of science.
In 1997, Drew Weissman, a respected immunologist, moved to UPenn. This was long before the days where scientific publications were available online, and so the only way for scientists to peruse the latest research was to photocopy it from journals. “I found myself fighting over a photocopy machine in the department with this scientist called Katalin Karikó,” he remembered. ”So we started talking, and comparing what each other did.”
While Karikó’s academic status at UPenn remained lowly, Weissman had the funding to finance her experiments, and the two began a partnership. “This gave me optimism, and kept me going,” she said. “My salary was lower than the technician who worked next to me, but Drew was supportive and that’s what I concentrated on, not the roadblocks I’d had to face.”
Karikó and Weissman realised that the key to creating a form of mRNA which could be administered safely, was to identify which of the underlying nucleosides – the letters of RNA’s genetic code – were provoking the immune system and replace them with something else. In the early 2000s, Karikó happened across a study which showed that one of these letters, Uridine, could trigger certain immune receptors. It was the crucial piece of information she had been searching for.
In 2005, Karikó and Weissman published a study announcing a specifically modified form of mRNA, which replaced Uridine with an analog – a molecule which looked the same, but did not induce an immune response. It was a clever biological trick, and one which worked. When mice were injected with this modified mRNA, they lived. “I just remember Drew saying, ’Oh my god, it’s not immunogenic,’” said Karikó. “We realised at that moment that this would be very important, and it could be used in vaccines and therapies. So we published a paper, filed a patent, established a company, and then found there was no interest. Nobody invited us anywhere to talk about it, nothing.”
Unbeknown to them, however, some scientists were paying attention. Derrick Rossi, then a postdoctoral researcher at Stanford University, read Karikó and Weissman’s paper and was immediately intrigued. In 2010, Rossi co-founded a biotech company called Moderna, with a group of Harvard and MIT professors, with the specific aim of using modified mRNA to create vaccines and therapeutics. A decade on, Moderna is now one of the leaders in the Covid-19 vaccine race and valued at approximately $35 billion (£26b), after reporting that its mRNA based vaccine showed 94 per cent efficacy in a Phase III clinical trial.
But it was not novel infectious disease vaccines which got the world interested in mRNA again. Around the same time, Rossi was establishing Moderna, Karikó and Weissman were also finally managing to commercialise their finding, licensing their technology to a small German company called BioNTech, after five years of trying and failing.
Both Moderna and BioNTech – which had been founded by a Turkish born entrepreneur called Ugur Sahin - had their eye on the lucrative fields of cancer immunotherapy, cardiovascular and metabolic diseases. Now that Karikó and Weissman’s discovery made it possible to safely administer mRNA to patients, some of the original goals for mRNA back in the 1970s, had become viable possibilities again.
Vaccines were also on the horizon. In 2017, Moderna began developing a potential Zika virus vaccine, while in 2018 BioNTech entered into a partnership with Pfizer to develop mRNA vaccines for influenza, although the large scale funding which drives vaccine projects was still nowhere to be seen.
That has all changed in 2020. With the Covid-19 pandemic requiring vaccine development on an unprecedented scale, mRNA vaccine approaches held a clear advantage over the more traditional but time consuming method of using a dead or inactivated form of the virus to create an immune response. In April, Moderna received $483 million (£360m) from the US Biomedical Advanced Research and Development Authority to fasttrack its Covid-19 vaccine program.
Karikó has been at the helm of BioNTech’s Covid-19 vaccine development. In 2013, she accepted an offer to become Senior Vice President at BioNTech after UPenn refused to reinstate her to the faculty position she had been demoted from in 1995. “They told me that they’d had a meeting and concluded that I was not of faculty quality,” she said. ”When I told them I was leaving, they laughed at me and said, ‘BioNTech doesn’t even have a website.’”
Now, BioNTech is a household name, following reports last month that the mRNA Covid-19 vaccine it has co-developed with Pfizer works with more than 95 per cent efficacy. Along with Moderna, it is set to supply billions of doses around the globe by the end of 2021.
For Karikó, seeing the results of BioNTech’s Phase III trial, simply brought a sense of quiet satisfaction. “I didn’t jump or scream,” she said. “I expected that it would be very effective.”
But after so many years of adversity, and struggling to convince people that her research was worthwhile, she is still trying to comprehend the fact that her breakthrough in mRNA technology could now change the lives of billions around the world, and help end the global pandemic.
“I always wanted to help people, to try and get something into the clinic,” she said. “That was the motivation for me, and I was always optimistic. But to help that many people, I never imagined that. It makes me very happy to know that I’ve played a part in this success story.”
- Posts : 3470
Join date : 2014-10-29
Kapitalizam 1 : Akademija 0
_____
you cannot simply trust a language model when it tells you how it feels
- Guest
kad se setim svih onih tirada o tome kako moramo da bolje povežemo akademsku zajednicu i industriju
- Guest
Industrija bolje prepoznaje trenutne potrebe društva (one do petka u 17h)
- Posts : 3470
Join date : 2014-10-29
Meni vise upala u oci velicina ega na drugoj strani...
Edit: sad ozbiljno, ono cega sira javnost jos uvek nije svesna je da ce ova trka i proboj mRNA vakcina doneti u narednim godinama veliki napredak u koriscenju mRNA za lecenje drugih bolesti.
Edit: sad ozbiljno, ono cega sira javnost jos uvek nije svesna je da ce ova trka i proboj mRNA vakcina doneti u narednim godinama veliki napredak u koriscenju mRNA za lecenje drugih bolesti.
_____
you cannot simply trust a language model when it tells you how it feels
- Posts : 8696
Join date : 2016-10-04
Да, мислим да су зато у Америци и гурали нову технологију.
- Posts : 5601
Join date : 2016-01-26
Проблем је што је у Америци све приватизовано, па тако имаш Гуглове урбанисте (Sidewalks Labs) који раде посао који би требала да ради држава.
@Sotir
Гурали у Америци, изгурали код Турчина у Немачкој.
@Sotir
Гурали у Америци, изгурали код Турчина у Немачкој.
_____
Burundi is an exception among other nations because it is a country which gave God first place, a God who guards and protects from all misfortune.
Burundi... opskurno udruženje 20ak levičarskih intelektualaca, kojima je fetiš odbrana poniženih i uvredjenih.
- Posts : 7775
Join date : 2017-03-14
"Obavezno pročitajte članak o ovoj neverovatnoj ženi koja bi lako mogla dobiti Nobelovu nagradu za ovo otkriće"
i ja mislim da dobija Nobela, i zaslužila je
i ja mislim da dobija Nobela, i zaslužila je
- Posts : 82754
Join date : 2012-06-10
Pa ovi je pre svega prica o tome kako je neoliberalizacija unistila akademiju. Njen problem je bio upravo sto venture capitalists nisu hteli da joj daju funding.
_____
"Oni kroz mene gledaju u vas! Oni kroz njega gledaju u vas! Oni kroz vas gledaju u mene... i u sve nas."
Dragoslav Bokan, Novi putevi oftalmologije
- Posts : 7775
Join date : 2017-03-14
neoliberalizacija je unistila sve
- Posts : 13817
Join date : 2016-02-01
Meanwhile, Brazil is the country with the second-most deaths in the world from COVID. Many stories of people dying waiting for ICU spaces. Extreme suffering from lockdowns, disease or both. Yet Bolsonaro has no interest in the vaccine.
— Glenn Greenwald (@ggreenwald) December 29, 2020https://t.co/WKvtxvc5Rh pic.twitter.com/OAMsK9Jubr
- Posts : 3849
Join date : 2014-11-12
rumbeando wrote:https://www.livemint.com/science/health/efficacy-of-oxford-jabs-at-95-if-given-3-months-apart-sii-11609181643451.htmlEfficacy of Oxford jabs at 95% if given 3 months apart: SII
- SII is manufacturing 50-60 million doses of Covishield a month and will increase its capacity to 100 million doses by March after commissioning its third plant.
AstraZeneca Plc will soon release data showing that the effectiveness of its covid-19 vaccine rises to as much as 95% if the two shots are separated by about 2-3 months, said Adar Poonawalla, chief executive of Serum Institute of India (SII), the British company’s manufacturing partner.
“You’ll be hearing some good news from the UK very soon. It would be a 90-95% effective vaccine if you just keep a two-to-three months’ gap between dose 1 and dose 2. They will make that public with documentation," Poonawalla said at a press conference on Monday. He was speaking at the launch of the company’s pneumococcal conjugate vaccine, the first such indigenous vaccine, under the brand Pneumosil.
uh... opet su podelili podatke na brdo pod-pod-pod grupa i dobili dobar rezultat u jednoj od njih. kako ovo mene dovodi do ocaja, vi pojma nemate. ne samo za ovu vakcinu nego kao opsti naucni princip... a zna se da dovodi do toga da se od suma u signalu pravi velika galama. pri tom, uspesnost od 60-70% je sasvim solidna stvar u odnosu na alternativu, odnosno cekanje bolje vakcine jos pola godine do godinu i po (u zavisnosti od nivoa rizika).
_____
Warning: may contain irony.
- Posts : 3849
Join date : 2014-11-12
a u holandiji su dobili vakcine ali su odlozili davanje do osmog januara. oni su uvek u fazonu polako, ajde da odredimo neki tamo datum u buducnosti*, ne valja zuriti... jos su rekli da ih ne daju jer nisu jos napisali skript, tekst koji zdravstveni radnih izgovara kad ti daje vakcinu 
...narod pizdi.
* nama su jednom zakazali za popravku svetla na biciklu da dodjemo kroz dve nedelje u sasvim odredjeno doba dana
, + uobicajeno je kad pitas nekog da li hoce na kafu da ti predlozi datum kroz mesec-dva.
...narod pizdi. * nama su jednom zakazali za popravku svetla na biciklu da dodjemo kroz dve nedelje u sasvim odredjeno doba dana
, + uobicajeno je kad pitas nekog da li hoce na kafu da ti predlozi datum kroz mesec-dva._____
Warning: may contain irony.
паће
- Posts : 41642
Join date : 2012-02-12
Location : wife privilege
bemty wrote:a u holandiji su dobili vakcine ali su odlozili davanje do osmog januara. oni su uvek u fazonu polako, ajde da odredimo neki tamo datum u buducnosti*, ne valja zuriti... jos su rekli da ih ne daju jer nisu jos napisali skript, tekst koji zdravstveni radnih izgovara kad ti daje vakcinu
* nama su jednom zakazali za popravku svetla na biciklu da dodjemo kroz dve nedelje u sasvim odredjeno doba dana
И онда одговориш као онај Рус кад су му рекли да ће Ладу добити кроз пет година, 17. маја - пита јел' преподне или поподне. Шта ти је то па битно? Битно је, за поподне имам заказаног водоинсталатера.
_____
cousin for roasting the rakija
И кажем себи у сну, еј бре коњу па ти ни немаш озвучење, имаш оне две кутијице око монитора, видећеш кад се пробудиш...
- Posts : 8696
Join date : 2016-10-04
Опет нешто петљају значи. Као и први пут са пола дозе.bemty wrote:
uh... opet su podelili podatke na brdo pod-pod-pod grupa i dobili dobar rezultat u jednoj od njih. kako ovo mene dovodi do ocaja, vi pojma nemate. ne samo za ovu vakcinu nego kao opsti naucni princip... a zna se da dovodi do toga da se od suma u signalu pravi velika galama. pri tom, uspesnost od 60-70% je sasvim solidna stvar u odnosu na alternativu, odnosno cekanje bolje vakcine jos pola godine do godinu i po (u zavisnosti od nivoa rizika).
- Posts : 52540
Join date : 2017-11-16
bemty wrote:a u holandiji su dobili vakcine ali su odlozili davanje do osmog januara. oni su uvek u fazonu polako, ajde da odredimo neki tamo datum u buducnosti*, ne valja zuriti... jos su rekli da ih ne daju jer nisu jos napisali skript, tekst koji zdravstveni radnih izgovara kad ti daje vakcinu
* nama su jednom zakazali za popravku svetla na biciklu da dodjemo kroz dve nedelje u sasvim odredjeno doba dana
To je ono - ajde iduce godine u ponedeljak.
Jel moze malo preciznije?
Posle podne.
- Posts : 52540
Join date : 2017-11-16
паће wrote:bemty wrote:a u holandiji su dobili vakcine ali su odlozili davanje do osmog januara. oni su uvek u fazonu polako, ajde da odredimo neki tamo datum u buducnosti*, ne valja zuriti... jos su rekli da ih ne daju jer nisu jos napisali skript, tekst koji zdravstveni radnih izgovara kad ti daje vakcinu
* nama su jednom zakazali za popravku svetla na biciklu da dodjemo kroz dve nedelje u sasvim odredjeno doba dana
И онда одговориш као онај Рус кад су му рекли да ће Ладу добити кроз пет година, 17. маја - пита јел' преподне или поподне. Шта ти је то па битно? Битно је, за поподне имам заказаног водоинсталатера.
E to je to
- Posts : 13817
Join date : 2016-02-01
https://www.reuters.com/article/us-health-coronavirus-eu-astrazeneca/astrazeneca-vaccine-not-ready-for-quick-european-approval-watchdog-official-says-idUSKBN2930XCThe European Medicines Authority (EMA) will most likely not be able to approve the COVID-19 vaccine developed by drug maker AstraZeneca and the University of Oxford in January, the watchdog’s Deputy Executive Director Noel Wathion said.
“They have not even filed an application with us yet”, Wathion said in an interview with Belgian newspaper Het Nieuwsblad published on Tuesday.
European regulators have only received some information about the vaccine, Wathion said.
“Not even enough to warrant a conditional marketing licence”, he said. “We need additional data about the quality of the vaccine. And after that, the company has to formally apply.”
This made it “improbable” that an approval could already be granted next month, Wathion said.
- Posts : 13817
Join date : 2016-02-01
https://uk.reuters.com/article/idUKS8N2GK0B2Britain approves AstraZeneca/Oxford COVID-19 vaccine
Britain on Wednesday became the first country in the world to approve a coronavirus vaccine developed by Oxford University and AstraZeneca as it battles a major winter surge driven by a new, highly contagious variant of the virus.
“The government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise Oxford University/AstraZeneca’s COVID-19 vaccine for use,” the health ministry said.
https://uk.reuters.com/article/uk-health-coronavirus-britain-vaccine-in/uk-approves-astrazeneca-oxford-covid-19-vaccine-idUKKBN2940MZInstant View: UK approves AstraZeneca/Oxford COVID-19 vaccine
DANNY ALTMANN, PROFESSOR OF IMMUNOLOGY, IMPERIAL COLLEGE LONDON
“Scientists don’t use terms like ‘game-changer’ lightly, but that’s what this is. Currently, the virus is once again proving that it can devastate by outrunning even our most draconian efforts to break transmission by limiting contact. To get out of this debacle there is no alternative to having a significant majority of the population carrying a high level of neutralising antibodies. With today’s announcement, that comes within our grasp.
“I await the modelling, but I suspect this will speed things by several months. An immune population by the Spring starts to look feasible.”
MATT HANCOCK, UK SECRETARY OF STATE FOR HEALTH AND SOCIAL CARE
“This is a moment to celebrate British innovation - not only are we responsible for discovering the first treatment to reduce mortality for COVID-19, this vaccine will be made available to some of the poorest regions of the world at a low cost, helping protect countless people from this awful disease.
“It is a tribute to the incredible UK scientists at Oxford University and AstraZeneca whose breakthrough will help to save lives around the world. I want to thank every single person who has been part of this British success story. While it is a time to be hopeful, it is so vital everyone continues to play their part to drive down infections.”